New hope for kids with aggressive leukemia: trial tests powerful drug combos
NCT ID NCT06390319
Summary
This study is testing whether adding one of two targeted drugs, dasatinib or venetoclax, to standard chemotherapy can improve outcomes for children and young adults with newly diagnosed T-cell leukemia or lymphoma. The main goal is to see if more patients achieve a deep, early remission with no detectable cancer cells after the first phase of treatment. The therapy lasts about two years and involves multiple phases of chemotherapy, followed by long-term monitoring.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Rady Children's Hospital
RECRUITINGSan Diego, California, 92123, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Saint Francis Children's Hospital
RECRUITINGTulsa, Oklahoma, 74136, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.